Advertisement
"Dr. Asgharnejad is a leading CNS clinical development practitioner and weare delighted that she has chosen to join the CeNeRx team," said Daniel Burch,M.D., Executive Vice President of R&D and Chief Medical Officer of CeNeRx. "Weexpect her proven ability to lead successful clinical development programsaddressing a variety of CNS disorders and her deep knowledge of the evolvingclinical and regulatory landscape will contribute greatly to our progressgoing forward."
Advertisement
Dr. Asgharnejad's extensive industry experience includes more than 20years of clinical program design and management. In recent years, she wasresponsible for developing and implementing development strategies forcandidates at various clinical stages for disorders including unipolar andbipolar depression, ADHD, obesity and migraine. Dr. Asgharnejad has managedprojects at all phases of development, including successful new productsubmissions to the FDA.
"CeNeRx's pipeline of novel candidates for CNS-related disorders with highunmet need presents an exceptional opportunity to leverage my varied expertisein the clinical development of compounds for CNS and other conditions," saidDr. Asgharnejad. "I look forward to working with the CeNeRx team to advanceTyrima(TM), our lead RIMA anti-depressant, into Phase II trials and tosupporting the company's promising preclinical portfolio."
Dr. Asgharnejad received B.S. and Pharm.D. degrees from the University ofMinnesota. She is a frequent presenter at scientific and medical meetings andis a co-author of several scientific papers.
About CeNeRx BioPharma
CeNeRx (SEN-er-ex) is a privately held clinical stage biopharmaceuticalcompany developing and commercializing innovative treatments for diseases ofthe central nervous system. CeNeRx's most advanced compounds, reversibleinhibitors of monoamine oxidase, or RIMAs, are in late preclinical and Phase Idevelopment for the treatment of major depressive disorder. RIMAs may haveefficacy advantages over current agents for depression and are expected tohave a good safety profile. The company is also developing its preclinicalpipeline of selective cannabinoid compounds for the treatment of pain,glaucoma and obesity. More information about CeNeRx BioPharma can be found athttp://www.cenerx.comContact: GendeLLindheim BioCom Partners Barbara Lindheim 212 918-4642
SOURCE CeNeRx BioPharma, Inc.
